RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: Cato BioVentures
Biotech Funding: Still Playing Hard-to-Get
After a few lean years, biotechs raised $25 billion in 2010. For the majority of small companies however, funding remains difficult to find. Ernst & Young’s annual report on the biotechnology industry, Beyond Borders, was recently released and it paints … Continue reading
Posted in Clinical Trials, Industry News, Venture Capital
Tagged biotech, Cato BioVentures, clinical research, clinical trials, drug development, funding, nonclinical research, Orphan Drug Designations, R&D
Comments Off
Bridging the Valley of Death: Bringing New Drugs from the Bench to the Clinic
To bring a new medicine to the stage of clinical trial testing requires on the order of $500,000 to one million dollars and then seven to ten years of clinical trials and around $800 million dollars before getting to market. … Continue reading
Posted in Clinical Trials, Venture Capital
Tagged biotech, cancer, Cato BioVentures, clinical trials, CROs, drug development, funding, NIH, Phase 1, Phase 2, preclinical, toxicology, venture capital
Comments Off
Conference Recap – BayBio 2011
The BayBio Annual Conference 2011 was held on 20-21 April 2011 in Burlingame, CA. The event was attended by more than 1,000 San Francisco Bay Area biotech and life sciences professionals from over 400 companies. This year’s conference focused on … Continue reading
Posted in Conferences and Meetings, Venture Capital
Tagged BayBio, biotech, Cato BioVentures, clinical development, CROs, drug candidate, drug development, funding, marketing, nonprofits, Northern California, Orphan Drug Designations, Phase 1, Phase 2, regulatory strategy, risk, safety, venture capital
Comments Off
Recap of the 20th CED Biotech/Life Sciences Conference
The 20th Annual Council for Entrepreneurial Development (CED) Biotech/Life Science Conference was held on 21-22 February 2011 in Raleigh, North Carolina. Continue reading
Posted in Conferences and Meetings, Industry News, Venture Capital
Tagged biotech, capi, Cato BioVentures, Cato Research, clinical research, conference, development plan, drug development, funding, healthcare reform, Phase 2, Phase 3, venture capital
Comments Off
Biotech Financing: Those That Adapt to Change Will Survive
In the October issue of Biotechnology Focus, Cato Research’s very own Chief Financial Officer and Principal of Cato BioVentures, Daniel Pharand, discusses the recent shift and latest trends in financing within the biotechnology industry. “There have been a number of … Continue reading
Posted in Publications, Venture Capital
Tagged biotech, Cato BioVentures, Cato Research, fina, venture capital
1 Comment
